Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
𝛼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Pacific Biosciences Of California (PACB US)
Watchlist
11
Analysis
Health Care
•
United States
Pacific Biosciences of California Inc. has developed a novel approach to studying the synthesis and regulation of DNA, RNA and protein. The Company's system enables real-time analysis of biomolecules with single molecule resolution.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Rigetti Computing
•
26 Nov 2025 06:06
Back to Near-Term Bullish on SPX and Nasdaq 100; Supports Held at SPX 6480-6520 and QQQ $580-583
Back to Near-Term Bullish on $SPX and Nasdaq 100 $NDX; Crucial Supports Held at 6480-6520 on SPX and $580-$583 on $QQQ, we are near-term bullish as...
Vermilion Research
Follow
377 Views
Share
bullish
•
Thematic (Sector/Industry)
•
01 Dec 2020 03:35
MergerTalk:Broken Deals Do Not Necessarily Lead To Broken Investments
Our snapshot study reveals that abandoned merger targets can deliver even more lucrative investment opportunities more often than one might think
Robert Sassoon
Follow
564 Views
Share
bullish
•
S&P 500 INDEX
•
19 Sep 2018 20:19
U.S. Equity Strategy: Cyclicals Remain Leadership - Staples & Utilities Are Strengthening
Investors continue to prefer the stability of the U.S. relative to emerging markets. The recent declines recorded in emerging markets and their...
Vermilion Research
Follow
636 Views
Share
bullish
•
Thematic (Sector/Industry)
•
05 Jan 2018 09:35
Human Longevity
At KIS capital we try to keep ourselves at the forefront of technology and innovation, attempting to identify which industries may blossom, and...
KIS Capital Partners
860 Views
Share
bearish
•
Axbio International
•
07 May 2025 10:00
Axbio (安序源) Pre-IPO: First Take of the Deal
China's Axbio plans to raise $100 million in Hong Kong listing with CICC and SPDB as joint sponsors, but doubts remain on deal prospects after...
Ke Yan, CFA, FRM
Follow
649 Views
Share
1
2
3
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x